Dr Reddys Q2 gross margin declined 270 bps YoY, largely led by weak US (-9% YoY) sales. However, EBITDA margin improved 190 bps aided by cost optimization initiatives and lower R&D; which led to 10% YoY growth in EBITDA (~19% above our estimate).